Mazdutide 10 mg
Educational recon guide for a 10 mg Mazdutide research vial and once-weekly unit mapping. Research use only — dual GLP-1/glucagon agonist in clinical development.
Vial
10 mg
Your BAC water
2 mL
Concentration
5.00 mg/mL
Per unit
~50.0 mcg
Frequency
Once weekly subcutaneous (clinical trial pattern)
Route
Subcutaneous
Live reconstitution calculator
Defaults match this guide (10 mg + 2 mL BAC). Change water or dose and the unit tables below update automatically.
Step 1
Reconstitution
Peptide amount in the vial and how much bacteriostatic water you add.
Step 2
Your dose
Quick-select common research doses (includes 2.5 / 7.5 for dual-agonist ladders) or type any mg / mcg value.
Quick select (mg) — switch units or type any value
Suggested: 30-unit barrel (smallest that fits this draw).
Your draw
Results
Total draw
30 units
Volume
0.300 mL
Doses per vial
6.7
Syringes needed
1
Barrel
30-unit
Fits one syringe?
Yes
30-unit · 0.3 mL
Filled to 30 u
Fill one 30-unit U-100 syringe to about 30 units (0.300 mL).
Weekly research phases
Units and volumes recompute from your Step 1 concentration (2 mL BAC → 5.00 mg/mL · 50.0 mcg/unit).
Standard titration
Published obesity/overweight trials have used once-weekly titrations into the multi-mg range (examples include ladders toward ~3–6 mg weekly in phase 2; phase 3 work has studied ~4 mg and ~6 mg weekly). Research-market powder is not an approved pen product.
| Phase | Weekly dose | Units | Volume |
|---|---|---|---|
| Weeks 1–4 · 1.5 mg weekly | 1.50 mg1,500 mcg | 30 u | 0.30 mLLower educational start (mirrors low-end trial ladders) |
| Weeks 5–8 · 3 mg weekly | 3 mg3,000 mcg | 60 u | 0.60 mLCommon mid trial target class |
| Weeks 9–24 · 4.5–6 mg weekly | 4.50 mg4,500 mcg | 90 u | 0.90 mL4.5 mg shown; trials also use 6 mg arms |
Advanced / higher-end
Faster escalation discussed in research communities — not a clinical recommendation
| Phase | Weekly dose | Units | Volume |
|---|---|---|---|
| Higher trial-style · 6 mg weekly | 6 mg6,000 mcg | 120 u | 1.20 mLUpper common phase 2/3 weekly amount studied |
| Higher experimental · 9 mg weekly | 9 mg9,000 mcg | 180 u | 1.80 mLHigher-dose trial part discussed in some programs — GI tolerability critical |
Supplies planner
Using the guide’s phase ladder (1.5 mg → 3 mg → 4.5 mg weekly (phase ladder)) over a 12-week schedule. Set a dose in Step 2 to plan supplies at your own amount.
Your recon
2 mL · 5.00 mg/mL
Dose in plan
Phase ladder
Syringe size
100-unit
Horizon
12-week schedule
Mazdutide 10 mg vials
4 vials
~36 mg mg total peptide over this 12-week schedule at 1.5 mg → 3 mg → 4.5 mg weekly (phase ladder). Each vial holds 10 mg.
Bacteriostatic water
3 × 3 mL or 1 × 10 mL
2 mL BAC per vial × 4 vials = 8.0 mL total. Buy as 3× 3 mL bottles or 1× 10 mL bottle (whichever you stock).
U-100 insulin syringes (100-unit)
12+ syringes
About one 100-unit syringe per injection for this schedule. Keep a few spares.
Alcohol swabs & sharps
~32 swabs · 1 sharps container
Wipe vial stopper and injection site each time. Dispose needles in a proper sharps container.
Reconstitution steps
- Allow the lyophilized 10 mg Mazdutide vial and bacteriostatic water to reach room temperature.
- Draw 2.0 mL bacteriostatic water (default for this guide).
- Inject BAC slowly down the inner wall of the vial — avoid blasting the powder cake.
- Gently swirl or roll until the solution is clear. Do not shake hard (foaming).
- Label with recon date and concentration (e.g. "5.0 mg/mL — 2 mL BAC").
- Refrigerate at 2–8 °C (35–46 °F), protected from light. Prefer using a reconstituted multi-dose vial within ~28 days with sterile technique.
Storage
Lyophilized
Keep dry powder cold and dark when possible (−20 °C / −4 °F preferred for long-term research stock).
Reconstituted
Refrigerate at 2–8 °C (35–46 °F). Avoid freeze–thaw of the working solution. Prefer finishing within ~28 days.
- ·Write recon date and BAC volume on the label.
- ·Protect from light during storage.
- ·Discard if cloudy, particulates, or odd odor appear after reconstitution.
Protocol notes
- ·Once-weekly dual GLP-1/glucagon agonist — not the same as daily liraglutide or weekly semaglutide alone.
- ·Titrate for GI tolerability; trial designs use stepped weekly escalation.
- ·Research use only. Not medical advice.
Research context & considerations
Mazdutide is an investigational dual agonist studied in China and elsewhere for overweight/obesity and metabolic endpoints. Catalog research vials are not approved medicines.
- ·GI adverse events dominate (nausea, diarrhea) in trials.
- ·GLP-1-class cautions apply (gallbladder, pancreatitis discussions, MTC/MEN2 framing on related approved products).
- ·Not FDA-approved as a research-vial consumer product.
- ·Pregnancy out of scope.
Catalog match
Mazdutide
10mg x 10 vials · from $65